Wednesday, April 23, 2014

Pharmacyclics Announces Presentation of Phase III and Long Term …

Pharmacyclics, Inc. announced that data from the Phase III PCYC-1112 (RESONATE™) study of single agent IMBRUVICA™ (ibrutinib) vs. ofatumumab, an established therapy in relapsed refractory CLL, as well as data from an Independent Efficacy Evaluation of IMBRUVICA after three years of follow-up, will be presented at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting in Chicago, Illinois May 30 - June 3, 2014. IMBRUVICA is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc. More …

Wednesday, April 23, 2014

Emergent BioSolutions Receives Orphan Drug Designation for BioThrax …

Emergent BioSolutions Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BioThrax® (Anthrax Vaccine Adsorbed) for post-exposure prophylaxis (PEP) of anthrax disease resulting from suspected or confirmed exposure to Bacillus anthracis. rphan status is given to drugs and biologics that are being developed to treat rare medical conditions, specifically those affecting fewer than 200,000 persons in the U.S. This designation provides incentives to the BioThrax PEP Program, including the waiver of the Biologics License Application (BLA) … More …

Wednesday, April 23, 2014

Repeats in Human DNA May Aggravate Autism Symptoms

Certain DNA repeats that increased exponentially during human evolution are directly related to the severity of autism symptoms, according to a preliminary study published 20 March in PLoS Genetics 1The repeats each span 65 amino acids and are collectively referred to as DUF1220, for ‘domain of unknown function.’ There are six types of these repeats, each with a slightly different sequence and all of which diverged from a common ancestor. More …